{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:57:20Z","timestamp":1790899040500,"version":"4.1.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypertriglyceridemia (HTG) is highly prevalent among patients with chronic kidney disease (CKD) and plays a critical role in both the progression of nephropathy and the increased risk of cardiovascular events. The underlying pathophysiology involves metabolic disturbances of triglyceride (TG)-rich lipoproteins, leading to lipid accumulation within renal cells. This accumulation triggers lipotoxicity, oxidative stress, and inflammatory cascades that ultimately contribute to renal fibrosis. In advanced stages of CKD, statins demonstrate limited efficacy, whereas emerging therapeutic agents show promising potential. RNA-based gene therapies targeting apolipoprotein C-III and angiopoietin-like protein 3 effectively reduce TG levels while maintaining a favorable renal safety profile. Additionally, agents such as pemafibrate, PCSK9 inhibitors, sodium\u2013glucose cotransporter-2 inhibitors, and glucagon-like peptide-1 receptor agonists not only lower lipid levels but also confer significant cardiorenal protective effects. Consequently, the management of HTG in CKD should transition from a singular lipid-lowering focus to a comprehensive, stratified approach that targets the interconnected pathways of lipotoxicity, inflammation, and fibrosis, with the ultimate goal of improving cardiorenal outcomes.<\/jats:p>","DOI":"10.1186\/s12944-026-02862-0","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T08:34:44Z","timestamp":1768898084000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Hypertriglyceridemia in chronic kidney disease: pathophysiological mechanisms, cardiovascular risk, and emerging therapeutics"],"prefix":"10.1186","volume":"25","author":[{"given":"Dandan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanju","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"issue":"3","key":"2862_CR1","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1016\/S2214-109X(23)00570-3","volume":"12","author":"AK Bello","year":"2024","unstructured":"Bello AK, Okpechi IG, Levin A, Ye F, Damster S, Arruebo S, et al. An update on the global disparities in kidney disease burden and care across world countries and regions. Lancet Glob Health. 2024;12(3):e382\u201395. https:\/\/doi.org\/10.1016\/S2214-109X(23)00570-3.","journal-title":"Lancet Glob Health"},{"issue":"7","key":"2862_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","volume":"20","author":"A Francis","year":"2024","unstructured":"Francis A, Harhay MN, Ong ACM, Tummalapalli SL, Ortiz A, Fogo AB, et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol. 2024;20(7):473\u201385. https:\/\/doi.org\/10.1038\/s41581-024-00820-6.","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"2862_CR3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41440-022-01041-9","volume":"46","author":"A Kaneyama","year":"2023","unstructured":"Kaneyama A, Hirata A, Hirata T, Imai Y, Kuwabara K, Funamoto M, et al. Impact of hypertension and diabetes on the onset of chronic kidney disease in a general Japanese population. Hypertens Res. 2023;46(2):311\u201320. https:\/\/doi.org\/10.1038\/s41440-022-01041-9.","journal-title":"Hypertens Res"},{"issue":"5","key":"2862_CR4","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1177\/2047487316679904","volume":"24","author":"A Hirata","year":"2017","unstructured":"Hirata A, Okamura T, Sugiyama D, Kuwabara K, Kadota A, Fujiyoshi A, et al. Impacts of chronic kidney disease and diabetes on cardiovascular mortality in a general Japanese population: a 20-year follow-up of the NIPPON DATA90 study. Eur J Prev Cardiol. 2017;24(5):505\u201313. https:\/\/doi.org\/10.1177\/2047487316679904.","journal-title":"Eur J Prev Cardiol"},{"issue":"11","key":"2862_CR5","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41581-022-00616-6","volume":"18","author":"K Matsushita","year":"2022","unstructured":"Matsushita K, Ballew SH, Wang AYM, Kalyesubula R, Schaeffner E, Agarwal R. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nat Rev Nephrol. 2022;18(11):696\u2013707. https:\/\/doi.org\/10.1038\/s41581-022-00616-6.","journal-title":"Nat Rev Nephrol"},{"issue":"7","key":"2862_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrcardio.2017.31","volume":"14","author":"\u017d Reiner","year":"2017","unstructured":"Reiner \u017d. Hypertriglyceridaemia and risk of coronary artery disease. Nat Rev Cardiol. 2017;14(7):401\u201311. https:\/\/doi.org\/10.1038\/nrcardio.2017.31.","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"2862_CR7","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurjpc\/zwad330","volume":"31","author":"HB Park","year":"2024","unstructured":"Park HB, Arsanjani R, Hong SJ, Yi JJ, Yi SW. Impact of hypertriglyceridaemia on cardiovascular mortality according to low-density lipoprotein cholesterol in a 15.6-million population. Eur J Prev Cardiol. 2024;31(3):280\u201390. https:\/\/doi.org\/10.1093\/eurjpc\/zwad330.","journal-title":"Eur J Prev Cardiol"},{"issue":"12","key":"2862_CR8","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/clc.23923","volume":"45","author":"A Shaik","year":"2022","unstructured":"Shaik A, Kosiborod M, de Lemos JA, Gao Q, Mues KE, Alam S, et al. Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from getting to an improved understanding of low-density lipoprotein cholesterol and dyslipidemia management (GOULD). Clin Cardiol. 2022;45(12):1303\u201310. https:\/\/doi.org\/10.1002\/clc.23923.","journal-title":"Clin Cardiol"},{"key":"2862_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2025.119146","volume":"403","author":"D Tramontano","year":"2025","unstructured":"Tramontano D, D\u2019Erasmo L, Larouche M, Brisson D, Lauzi\u00e8re A, Di Costanzo A, et al. The vicious circle of chronic kidney disease and hypertriglyceridemia: what is first, the hen or the egg? Atherosclerosis. 2025;403:119146. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.119146.","journal-title":"Atherosclerosis"},{"issue":"4","key":"2862_CR10","doi-asserted-by":"publisher","first-page":"691","DOI":"10.18388\/abp.2020_6462","volume":"69","author":"A Cader","year":"2022","unstructured":"Cader A, St\u0119pniewska J, R\u00f3\u017ca\u0144ski J. Lipid disorders \u2014 the comparison between general population and haemodialyzed patients. Will the oral fat tolerance test improve the diagnostic? Acta Biochim Pol. 2022;69(4):691\u20136. https:\/\/doi.org\/10.18388\/abp.2020_6462.","journal-title":"Acta Biochim Pol"},{"key":"2862_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2025.120653","volume":"579","author":"J Leivisk\u00e4","year":"2026","unstructured":"Leivisk\u00e4 J, Sundvall J, Jauhiainen M, Kotseva K, Tuomilehto J, De Backer G, et al. Residual cardiovascular risk is tracked by apolipoprotein B in coronary patients with elevated serum triglyceride levels: the ESC EORP EUROASPIRE IV survey. Clin Chim Acta. 2026;579:120653. https:\/\/doi.org\/10.1016\/j.cca.2025.120653.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"2862_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-22831-4","volume":"15","author":"AK Yirdaw","year":"2025","unstructured":"Yirdaw AK, Ayele YY, Alemu H, Tesfaye T, Hailu W, Getahun D. Prevalence and associated factors of hyperuricemia in chronic kidney disease: evidence from a single-center hospital-based study in Ethiopia, 2024. Sci Rep. 2025;15(1):38938. https:\/\/doi.org\/10.1038\/s41598-025-22831-4.","journal-title":"Sci Rep"},{"issue":"11","key":"2862_CR13","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/ki.2010.311","volume":"78","author":"JM Saland","year":"2010","unstructured":"Saland JM, Pierce CB, Mitsnefes MM, Flynn JT, Goebel J, Kupferman JC, et al. Dyslipidemia in children with chronic kidney disease. Kidney Int. 2010;78(11):1154\u201363. https:\/\/doi.org\/10.1038\/ki.2010.311.","journal-title":"Kidney Int"},{"key":"2862_CR14","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s00467-016-3350-4","volume":"31","author":"P Khandelwal","year":"2016","unstructured":"Khandelwal P, Murugan V, Hari S, Lakshmy R, Sinha A, Hari P, et al. Dyslipidemia, carotid intima-media thickness and endothelial dysfunction in children with chronic kidney disease. Pediatr Nephrol. 2016;31:1313\u201320. https:\/\/doi.org\/10.1007\/s00467-016-3350-4.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"2862_CR15","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12882-022-02932-2","volume":"23","author":"M Weldegiorgis","year":"2022","unstructured":"Weldegiorgis M, Woodward M. Elevated triglycerides and reduced high-density lipoprotein cholesterol are independently associated with the onset of advanced chronic kidney disease: a cohort study of 911,360 individuals from the united Kingdom. BMC Nephrol. 2022;23(1):312. https:\/\/doi.org\/10.1186\/s12882-022-02932-2.","journal-title":"BMC Nephrol"},{"key":"2862_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejim.2023.02.019","volume":"111","author":"R Pontremoli","year":"2023","unstructured":"Pontremoli R, Desideri G, Arca M, Temporelli PL, Perrone V, Dovizio M, et al. Hypertriglyceridemia is associated with decline of estimated glomerular filtration rate and risk of end-stage kidney disease in a real-word Italian cohort: evidence from the TG-RENAL study. Eur J Intern Med. 2023;111:90\u20136. https:\/\/doi.org\/10.1016\/j.ejim.2023.02.019.","journal-title":"Eur J Intern Med"},{"issue":"6","key":"2862_CR17","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1159\/000502511","volume":"9","author":"PP Toth","year":"2019","unstructured":"Toth PP, Philip S, Hull M, Granowitz C. Elevated triglycerides (\u2265 150 mg\/dL) and high triglycerides (200\u2013499 mg\/dL) are significant predictors of hospitalization for new-onset kidney disease: a real-world analysis of high-risk statin-treated patients. Cardiorenal Med. 2019;9(6):400\u20137. https:\/\/doi.org\/10.1159\/000502511.","journal-title":"Cardiorenal Med"},{"issue":"11","key":"2862_CR18","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1111\/dom.14502","volume":"23","author":"L Gong","year":"2021","unstructured":"Gong L, Wang C, Ning G, Wang W, Chen G, Wan Q, et al. High concentrations of triglycerides are associated with diabetic kidney disease in new-onset type 2 diabetes in China: findings from the China Cardiometabolic Disease and Cancer Cohort (4C) Study. Diabetes Obes Metab. 2021;23(11):2551\u201360. https:\/\/doi.org\/10.1111\/dom.14502.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"2862_CR19","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1161\/CIRCULATIONAHA.113.002529","volume":"129","author":"FM Sacks","year":"2014","unstructured":"Sacks FM, Hermans MP, Fioretto P, Valensi P, Davis T, Horton E, et al. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation. 2014;129(9):999\u20131008. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.002529.","journal-title":"Circulation"},{"issue":"2","key":"2862_CR20","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jacc.2022.10.019","volume":"81","author":"M Balling","year":"2023","unstructured":"Balling M, Afzal S, Davey Smith G, Varbo A, Langsted A, Kamstrup PR, et al. Elevated LDL triglycerides and atherosclerotic risk. J Am Coll Cardiol. 2023;81(2):136\u201352. https:\/\/doi.org\/10.1016\/j.jacc.2022.10.019.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2862_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-023-02001-z","volume":"23","author":"CS Kuo","year":"2024","unstructured":"Kuo CS, Kuo NR, Yeh YK, Lee YJ, Chuang LM, Chen HF, et al. Residual risk of cardiovascular complications in statin-using patients with type 2 diabetes: the Taiwan Diabetes Registry Study. Lipids Health Dis. 2024;23(1):24. https:\/\/doi.org\/10.1186\/s12944-023-02001-z.","journal-title":"Lipids Health Dis"},{"issue":"20","key":"2862_CR22","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-Kidney-Metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023;148(20):1606\u201335. https:\/\/doi.org\/10.1161\/CIR.0000000000001184.","journal-title":"Circulation"},{"issue":"11","key":"2862_CR23","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019343","volume":"10","author":"S Saadatagah","year":"2021","unstructured":"Saadatagah S, Pasha AK, Alhalabi L, Sandhyavenu H, Farwati M, Smith CY, et al. Coronary heart disease risk associated with primary isolated hypertriglyceridemia: a population-based study. J Am Heart Assoc. 2021;10(11):e019343. https:\/\/doi.org\/10.1161\/JAHA.120.019343.","journal-title":"J Am Heart Assoc"},{"issue":"13","key":"2862_CR24","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1093\/eurjpc\/zwaf104","volume":"32","author":"E Aaseth","year":"2025","unstructured":"Aaseth E, Halvorsen S, Helseth R, Gravning J. Remnant cholesterol, plasma triglycerides, and risk of cardiovascular disease events in young adults: a prospective cohort study. Eur J Prev Cardiol. 2025;32(13):1181\u20139. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf104.","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"2862_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01921-5","volume":"22","author":"FPB Kristensen","year":"2023","unstructured":"Kristensen FPB, Christensen DH, Mortensen MB, Maeng M, Kahlert J, S\u00f8rensen HT, et al. Triglycerides and risk of cardiovascular events in statin-treated patients with newly diagnosed type 2 diabetes: a Danish cohort study. Cardiovasc Diabetol. 2023;22(1):187. https:\/\/doi.org\/10.1186\/s12933-023-01921-5.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"2862_CR26","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/s41440-023-01197-y","volume":"46","author":"T Uemura","year":"2023","unstructured":"Uemura T, Nishimoto M, Eriguchi M, Tamaki H, Tasaki H, Furuyama R, et al. Association of triglycerides to high-density lipoprotein cholesterol ratio with incident cardiovascular disease but not end-stage kidney disease among patients with biopsy-proven diabetic nephropathy. Hypertens Res. 2023;46(6):1423\u201332. https:\/\/doi.org\/10.1038\/s41440-023-01197-y.","journal-title":"Hypertens Res"},{"issue":"9","key":"2862_CR27","doi-asserted-by":"publisher","first-page":"101359","DOI":"10.1016\/j.jacbts.2025.101359","volume":"10","author":"NA Reilly","year":"2025","unstructured":"Reilly NA, Mulder JWCM, Dekkers KF, Kuipers TB, van Vark-van LC, Mulder MT, et al. Triglycerides and T cells in cardiovascular risk: inflammatory transcriptomic profile in hypertriglyceridemia patients\u2019 T cells. JACC Basic Transl Sci. 2025;10(9):101359. https:\/\/doi.org\/10.1016\/j.jacbts.2025.101359.","journal-title":"JACC Basic Transl Sci"},{"key":"2862_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1544591","volume":"16","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, Zhou K, Li Y, Dong W, Sun Y, Wu H, et al. Associations between the triglyceride-glucose index and the risk of heart failure in patients undergoing maintenance hemodialysis: a retrospective cohort study. Front Endocrinol (Lausanne). 2025;16:1544591. https:\/\/doi.org\/10.3389\/fendo.2025.1544591.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2862_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2215\/CJN.07320619","volume":"15","author":"JA Lamprea-Montealegre","year":"2020","unstructured":"Lamprea-Montealegre JA, Staplin N, Herrington WG, Haynes R, Emberson J, Baigent C, et al. Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD. Clin J Am Soc Nephrol. 2020;15(1):47\u201360. https:\/\/doi.org\/10.2215\/CJN.07320619.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"39","key":"2862_CR30","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1093\/eurheartj\/ehad337","volume":"44","author":"E Bj\u00f6rnson","year":"2023","unstructured":"Bj\u00f6rnson E, Adiels M, Taskinen MR, Burgess S, Rawshani A, Boren J, et al. Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study. Eur Heart J. 2023;44(39):4186\u201395. https:\/\/doi.org\/10.1093\/eurheartj\/ehad337.","journal-title":"Eur Heart J"},{"key":"2862_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.bbrc.2022.06.067","volume":"620","author":"Y Fujino","year":"2022","unstructured":"Fujino Y, Yasuda-Yamahara M, Tanaka-Sasaki Y, Kuwagata S, Yamahara K, Tagawa A, et al. Limited effects of systemic or renal lipoprotein lipase deficiency on renal physiology and diseases. Biochem Biophys Res Commun. 2022;620:15\u201320. https:\/\/doi.org\/10.1016\/j.bbrc.2022.06.067.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"2862_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-025-02764-7","volume":"24","author":"F Wang","year":"2025","unstructured":"Wang F, Huang W, Wang Z, Zhang D, Qiao H, Chen N, et al. Insulin resistance surrogates predict major adverse cardiovascular events in patients with heart failure with preserved ejection fraction and chronic kidney disease: a retrospective cohort study. Lipids Health Dis. 2025;24(1):349. https:\/\/doi.org\/10.1186\/s12944-025-02764-7.","journal-title":"Lipids Health Dis"},{"issue":"1","key":"2862_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05466-3","volume":"22","author":"Y Li","year":"2024","unstructured":"Li Y, Chen S, Yang Q, Liu X, Zhou W, Kang T, et al. The ANGPTL4\u2013HIF-1\u03b1 loop: a critical regulator of renal interstitial fibrosis. J Transl Med. 2024;22(1):649. https:\/\/doi.org\/10.1186\/s12967-024-05466-3.","journal-title":"J Transl Med"},{"issue":"12","key":"2862_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1681\/ASN.2021040503","volume":"32","author":"SJ Schunk","year":"2021","unstructured":"Schunk SJ, Hermann J, Sarakpi T, Triem S, Lellig M, Hahm E, et al. Guanidinylated apolipoprotein C3 (ApoC3) associates with kidney and vascular injury. J Am Soc Nephrol. 2021;32(12):1\u201315. https:\/\/doi.org\/10.1681\/ASN.2021040503.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"2862_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/genes12111687","volume":"12","author":"J Wang","year":"2021","unstructured":"Wang J, Liu L, He K, Gao B, Wang F, Zhao M, et al. Umod polymorphisms associated with kidney function, serum uromodulin and risk of mortality among patients with chronic kidney disease, results from the C-stride study. Genes. 2021;12(11):1687. https:\/\/doi.org\/10.3390\/genes12111687.","journal-title":"Genes"},{"key":"2862_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1434145","volume":"15","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Ou G, Peng L, Pan J, Zhang S, Shi J. Genetic association analysis of lipid-lowering drug target genes in chronic kidney disease. Front Endocrinol (Lausanne). 2025;15:1434145. https:\/\/doi.org\/10.3389\/fendo.2024.1434145.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"2862_CR37","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1093\/ckj\/sfab113","volume":"14","author":"M Bermudez-Lopez","year":"2021","unstructured":"Bermudez-Lopez M, Perpi\u00f1an H, Amigo N, Castro E, Alonso N, Mauricio D, et al. Advanced lipoprotein parameters could better explain atheromatosis in non-diabetic chronic kidney disease patients. Clin Kidney J. 2021;14(12):2591\u20139. https:\/\/doi.org\/10.1093\/ckj\/sfab113.","journal-title":"Clin Kidney J"},{"key":"2862_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104778","volume":"156","author":"K Su","year":"2020","unstructured":"Su K, Yi B, Yao BQ, Xia T, Yang YF, Zhang ZH, et al. Liraglutide attenuates renal tubular ectopic lipid deposition in rats with diabetic nephropathy by inhibiting lipid synthesis and promoting lipolysis. Pharmacol Res. 2020;156:104778. https:\/\/doi.org\/10.1016\/j.phrs.2020.104778.","journal-title":"Pharmacol Res"},{"issue":"4","key":"2862_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/biom15040498","volume":"15","author":"X Zheng","year":"2025","unstructured":"Zheng X, Guo X, Chen Y, Zhuang K, Gong N, Fu Y, et al. Integration of DNA methylome and transcriptome analysis to identify novel epigenetic targets in the acute kidney injury\u2013chronic kidney disease transition. Biomolecules. 2025;15(4):498. https:\/\/doi.org\/10.3390\/biom15040498.","journal-title":"Biomolecules"},{"issue":"4","key":"2862_CR40","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1152\/ajprenal.00438.2019","volume":"318","author":"KC Mcpherson","year":"2020","unstructured":"Mcpherson KC, Shields CA, Poudel B, Johnson AC, Taylor L, Stubbs C, et al. Altered renal hemodynamics is associated with glomerular lipid accumulation in obese Dahl salt-sensitive leptin receptor mutant rats. Am J Physiol Ren Physiol. 2020;318(4):911\u201321. https:\/\/doi.org\/10.1152\/ajprenal.00438.2019.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"1","key":"2862_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02068-4","volume":"23","author":"Y Chen","year":"2025","unstructured":"Chen Y, Dai Y, Huang Y, Zhang L, Zhang C, Gao H, et al. Inhibition of tubular epithelial cells ferroptosis alleviates renal interstitial fibrosis by reducing lipid hydroperoxides and TGF-\u03b2\/Smad signaling. Cell Commun Signal. 2025;23(1):81. https:\/\/doi.org\/10.1186\/s12964-025-02068-4.","journal-title":"Cell Commun Signal"},{"issue":"18","key":"2862_CR42","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.182534","volume":"9","author":"S Hasegawa","year":"2024","unstructured":"Hasegawa S, Nangaku M, Takenaka Y, Kitayama C, Li Q, Saipidin M, et al. Organelle communication maintains mitochondrial and endosomal homeostasis during podocyte lipotoxicity. JCI Insight. 2024;9(18):e182534. https:\/\/doi.org\/10.1172\/jci.insight.182534.","journal-title":"JCI Insight"},{"issue":"2","key":"2862_CR43","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2023.2292753","volume":"45","author":"H Niu","year":"2023","unstructured":"Niu H, Ren X, Tan E, Wan X, Wang Y, Shi H, et al. CD36 deletion ameliorates diabetic kidney disease by restoring fatty acid oxidation and improving mitochondrial function. Ren Fail. 2023;45(2):2292753. https:\/\/doi.org\/10.1080\/0886022X.2023.2292753.","journal-title":"Ren Fail"},{"issue":"5","key":"2862_CR44","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1681\/ASN.2016070731","volume":"28","author":"T Yamamoto","year":"2017","unstructured":"Yamamoto T, Takabatake Y, Takahashi A, Kimura T, Namba T, Matsuda J, et al. High-fat diet-induced lysosomal dysfunction and impaired autophagic flux contribute to lipotoxicity in the kidney. J Am Soc Nephrol. 2017;28(5):1534\u201351. https:\/\/doi.org\/10.1681\/ASN.2016070731.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2862_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010350","volume":"22","author":"F Juszczak","year":"2020","unstructured":"Juszczak F, Vlassembrouck M, Botton O, Zwakhals T, Decarnoncle M, Tassin A, et al. Delayed exercise training improves obesity-induced chronic kidney disease by activating AMPK pathway in high-fat diet-fed mice. Int J Mol Sci. 2020;22(1):350. https:\/\/doi.org\/10.3390\/ijms22010350.","journal-title":"Int J Mol Sci"},{"key":"2862_CR46","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5828120","volume":"2018","author":"Y Liu","year":"2018","unstructured":"Liu Y, Wang Y, Ding W, Wang Y. Mito-TEMPO alleviates renal fibrosis by reducing inflammation, mitochondrial dysfunction, and endoplasmic reticulum stress. Oxid Med Cell Longev. 2018;2018:5828120. https:\/\/doi.org\/10.1155\/2018\/5828120.","journal-title":"Oxid Med Cell Longev"},{"issue":"7","key":"2862_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11071387","volume":"11","author":"Z Chen","year":"2022","unstructured":"Chen Z, Shrestha R, Yang X, Wu X, Jia J, Chiba H, et al. Oxidative stress and lipid dysregulation in lipid droplets: a connection to chronic kidney disease revealed in human kidney cells. Antioxidants. 2022;11(7):1387. https:\/\/doi.org\/10.3390\/antiox11071387.","journal-title":"Antioxidants"},{"issue":"2","key":"2862_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102046","volume":"24","author":"A Harzandi","year":"2021","unstructured":"Harzandi A, Lee S, Bidkhori G, Saha S, Hendry BM, Mardinoglu A, et al. Acute kidney injury leading to CKD is associated with a persistence of metabolic dysfunction and hypertriglyceridemia. iScience. 2021;24(2):102046. https:\/\/doi.org\/10.1016\/j.isci.2021.102046.","journal-title":"iScience"},{"issue":"10","key":"2862_CR49","doi-asserted-by":"publisher","first-page":"5232","DOI":"10.3390\/ijms25105232","volume":"25","author":"Y Shuai","year":"2024","unstructured":"Shuai Y, Xu N, Zhao C, Yang F, Ning Z, Li G. MicroRNA-10 family promotes renal fibrosis through the VASH-1\/Smad3 pathway. Int J Mol Sci. 2024;25(10):5232. https:\/\/doi.org\/10.3390\/ijms25105232.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2862_CR50","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12882-021-02391-1","volume":"22","author":"X Xu","year":"2021","unstructured":"Xu X, Huang X, Zhang L, Huang X, Qin Z, Hua F. Adiponectin protects obesity-related glomerulopathy by inhibiting ROS\/NF-\u03baB\/NLRP3 inflammation pathway. BMC Nephrol. 2021;22(1):218. https:\/\/doi.org\/10.1186\/s12882-021-02391-1.","journal-title":"BMC Nephrol"},{"key":"2862_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2025.123755","volume":"376","author":"C Ren","year":"2025","unstructured":"Ren C, Mi T, Zhang Z, Jin L, Wang Z, Kong X, et al. Targeting interferon regulatory factor 7 alleviates renal fibrosis by inhibiting macrophage-to-myofibroblast transition. Life Sci. 2025;376:123755. https:\/\/doi.org\/10.1016\/j.lfs.2025.123755.","journal-title":"Life Sci"},{"issue":"2","key":"2862_CR52","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1681\/ASN.2016121362","volume":"29","author":"X Qiao","year":"2018","unstructured":"Qiao X, Rao P, Zhang Y, Liu L, Pang M, Wang H, et al. Redirecting TGF-\u03b2 signaling through the \u03b2-Catenin\/ Foxo complex prevents kidney fibrosis. J Am Soc Nephrol. 2018;29(2):557\u201370. https:\/\/doi.org\/10.1681\/ASN.2016121362.","journal-title":"J Am Soc Nephrol"},{"key":"2862_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2023.100716","volume":"21","author":"C Ding","year":"2023","unstructured":"Ding C, Wang B, Lai XF, Guo Y, Tesch G, Ding X, et al. Cellular delivery of relaxin-2 mRNA as a potential treatment for kidney fibrosis. Mater Today Bio. 2023;21:100716. https:\/\/doi.org\/10.1016\/j.mtbio.2023.100716.","journal-title":"Mater Today Bio"},{"key":"2862_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01201","volume":"11","author":"AA Pinar","year":"2020","unstructured":"Pinar AA, Yuferov A, Gaspari TA, Samuel CS. Relaxin can mediate its anti-fibrotic effects by targeting the myofibroblast NLRP3 inflammasome at the level of caspase-1. Front Pharmacol. 2020;11:1201. https:\/\/doi.org\/10.3389\/fphar.2020.01201.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2862_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-020-0823-5","volume":"22","author":"S Yamashita","year":"2020","unstructured":"Yamashita S, Masuda D, Matsuzawa Y. Pemafibrate, a new selective PPAR\u03b1 modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases. Curr Atheroscler Rep. 2020;22(1):5. https:\/\/doi.org\/10.1007\/s11883-020-0823-5.","journal-title":"Curr Atheroscler Rep"},{"key":"2862_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121590","volume":"321","author":"Y Horinouchi","year":"2023","unstructured":"Horinouchi Y, Murashima Y, Yamada Y, Yoshioka S, Fukushima K, Kure T, et al. Pemafibrate inhibited renal dysfunction and fibrosis in a mouse model of adenine-induced chronic kidney disease. Life Sci. 2023;321:121590. https:\/\/doi.org\/10.1016\/j.lfs.2023.121590.","journal-title":"Life Sci"},{"issue":"2","key":"2862_CR57","doi-asserted-by":"publisher","first-page":"210","DOI":"10.5551\/jat.64887","volume":"32","author":"S Ishibashi","year":"2025","unstructured":"Ishibashi S, Arai H, Yokote K, Araki E, Watanabe M, Nakanishi M, et al. Pharmacokinetics and safety of pemafibrate in patients with both dyslipidemia and severe renal impairment: a phase 4 study. J Atheroscler Thromb. 2025;32(2):210\u201325. https:\/\/doi.org\/10.5551\/jat.64887.","journal-title":"J Atheroscler Thromb"},{"issue":"3","key":"2862_CR58","doi-asserted-by":"publisher","first-page":"473","DOI":"10.4093\/dmj.2023.0370","volume":"48","author":"R Izumihara","year":"2024","unstructured":"Izumihara R, Nomoto H, Kito K, Yamauchi Y, Omori K, Shibayama Y, et al. Switching from conventional fibrates to pemafibrate has beneficial effects on the renal function of diabetic subjects with chronic kidney disease. Diabetes Metab J. 2024;48(3):473\u201381. https:\/\/doi.org\/10.4093\/dmj.2023.0370.","journal-title":"Diabetes Metab J"},{"issue":"4","key":"2862_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041481","volume":"12","author":"T Iwakura","year":"2023","unstructured":"Iwakura T, Yasu T, Tomoe T, Ueno A, Sugiyama T, Otani N, et al. Effect of pemafibrate on hemorheology in patients with hypertriglyceridemia and aggravated blood fluidity associated with type 2 diabetes or metabolic syndrome. J Clin Med. 2023;12(4):1481. https:\/\/doi.org\/10.3390\/jcm12041481.","journal-title":"J Clin Med"},{"issue":"7","key":"2862_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071838","volume":"15","author":"H Nomoto","year":"2023","unstructured":"Nomoto H, Kito K, Iesaka H, Oe Y, Kawata S, Tsuchida K, et al. Favorable effect of pemafibrate on insulin resistance and \u03b2-cell function in subjects with type 2 diabetes and hypertriglyceridemia: a subanalysis of the PARM-T2D study. Pharmaceutics. 2023;15(7):1838. https:\/\/doi.org\/10.3390\/pharmaceutics15071838.","journal-title":"Pharmaceutics"},{"issue":"1","key":"2862_CR61","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12933-021-01291-w","volume":"20","author":"K Yokote","year":"2021","unstructured":"Yokote K, Yamashita S, Arai H, Araki E, Matsushita M, Nojima T, et al. Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials. Cardiovasc Diabetol. 2021;20(1):96. https:\/\/doi.org\/10.1186\/s12933-021-01291-w.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"2862_CR62","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1080\/07853890.2018.1511919","volume":"50","author":"A Sahebkar","year":"2018","unstructured":"Sahebkar A, Simental-Mend\u00eda LE, Mikhailidis DP, Pirro M, Banach M, Sirtori CR, et al. Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials. Ann Med. 2018;50(7):565\u201375. https:\/\/doi.org\/10.1080\/07853890.2018.1511919.","journal-title":"Ann Med"},{"issue":"1","key":"2862_CR63","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1812792.","journal-title":"N Engl J Med"},{"issue":"13","key":"2862_CR64","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1056\/NEJMoa2507227","volume":"393","author":"BA Bergmark","year":"2025","unstructured":"Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, et al. Targeting APOC3 with olezarsen in moderate hypertriglyceridemia. N Engl J Med. 2025;393(13):1279\u201391. https:\/\/doi.org\/10.1056\/NEJMoa2507227.","journal-title":"N Engl J Med"},{"issue":"19","key":"2862_CR65","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","volume":"390","author":"BA Bergmark","year":"2024","unstructured":"Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, et al. Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. N Engl J Med. 2024;390(19):1770\u201380. https:\/\/doi.org\/10.1056\/NEJMoa2402309.","journal-title":"N Engl J Med"},{"issue":"19","key":"2862_CR66","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","volume":"390","author":"ESG Stroes","year":"2024","unstructured":"Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, Hegele RA, Arca M, Ballantyne CM, et al. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N Engl J Med. 2024;390(19):1781\u201392. https:\/\/doi.org\/10.1056\/NEJMoa2400201.","journal-title":"N Engl J Med"},{"issue":"1","key":"2862_CR67","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3390\/jcm12010168","volume":"12","author":"B Sosnowska","year":"2023","unstructured":"Sosnowska B, Adach W, Surma S, Rosenson RS, Banach M. Evinacumab, an ANGPTL3 inhibitor, in the treatment of dyslipidemia. J Clin Med. 2023;12(1):168. https:\/\/doi.org\/10.3390\/jcm12010168.","journal-title":"J Clin Med"},{"issue":"3","key":"2862_CR68","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/FJC.0000000000001073","volume":"78","author":"M Jin","year":"2021","unstructured":"Jin M, Meng F, Yang W, Liang L, Wang H, Fu Z. Efficacy and safety of evinacumab for the treatment of hypercholesterolemia: a meta-analysis. J Cardiovasc Pharmacol. 2021;78(3):394\u2013402. https:\/\/doi.org\/10.1097\/FJC.0000000000001073.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"17","key":"2862_CR69","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.3390\/molecules25173891","volume":"25","author":"DS Gesto","year":"2020","unstructured":"Gesto DS, Pereira CMS, Cerqueira NMFS, Sousa SF. An atomic-level perspective of HMG-CoA-reductase: the target enzyme to treat hypercholesterolemia. Molecules. 2020;25(17):3891. https:\/\/doi.org\/10.3390\/molecules25173891.","journal-title":"Molecules"},{"issue":"9","key":"2862_CR70","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.amjcard.2016.02.011","volume":"117","author":"BW Karlson","year":"2016","unstructured":"Karlson BW, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. A VOYAGER meta-analysis of the impact of Statin therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridemia. Am J Cardiol. 2016;117(9):1444\u20138. https:\/\/doi.org\/10.1016\/j.amjcard.2016.02.011.","journal-title":"Am J Cardiol"},{"issue":"3","key":"2862_CR71","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","volume":"353","author":"C Wanner","year":"2005","unstructured":"Wanner C, Krane V, M\u00e4rz W, Olschewski M, Mann JFE, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238\u201348. https:\/\/doi.org\/10.1056\/NEJMoa043545.","journal-title":"N Engl J Med"},{"issue":"14","key":"2862_CR72","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","volume":"360","author":"BC Fellstr\u00f6m","year":"2009","unstructured":"Fellstr\u00f6m BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa0810177.","journal-title":"N Engl J Med"},{"issue":"1","key":"2862_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01690-3","volume":"9","author":"X Bao","year":"2024","unstructured":"Bao X, Liang Y, Chang H, Cai T, Feng B, Gordon K, et al. Targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9): from bench to bedside. Signal Transduct Target Ther. 2024;9(1):13. https:\/\/doi.org\/10.1038\/s41392-023-01690-3.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"2862_CR74","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/MOL.0000000000000935","volume":"35","author":"PE St\u00fcrzebecher","year":"2024","unstructured":"St\u00fcrzebecher PE, Laufs U. Proprotein convertase subtilisin\/kexin type 9-inhibition across different patient populations. Curr Opin Lipidol. 2024;35(4):179\u201386. https:\/\/doi.org\/10.1097\/MOL.0000000000000935.","journal-title":"Curr Opin Lipidol"},{"issue":"18","key":"2862_CR75","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"issue":"22","key":"2862_CR76","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"issue":"1","key":"2862_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MOL.0000000000000565","volume":"30","author":"AC Burke","year":"2019","unstructured":"Burke AC, Telford DE, Huff MW. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol. 2019;30(1):1\u20139. https:\/\/doi.org\/10.1097\/MOL.0000000000000565.","journal-title":"Curr Opin Lipidol"},{"issue":"4","key":"2862_CR78","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s10557-021-07147-5","volume":"35","author":"CM Ballantyne","year":"2021","unstructured":"Ballantyne CM, Bays H, Catapano AL, Goldberg A, Ray KK, Saseen JJ. Role of bempedoic acid in clinical practice. Cardiovasc Drugs Ther. 2021;35(4):853\u201364. https:\/\/doi.org\/10.1007\/s10557-021-07147-5.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"15","key":"2862_CR79","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2215024.","journal-title":"N Engl J Med"},{"issue":"1","key":"2862_CR80","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.121.053766","volume":"144","author":"AJ Nelson","year":"2021","unstructured":"Nelson AJ, Pagidipati NJ, Aroda VR, Cavender MA, Green JB, Lopes RD, et al. Incorporating SGLT2i and GLP-1RA for cardiovascular and kidney disease risk reduction: call for action to the cardiology community. Circulation. 2021;144(1):74\u201384. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.053766.","journal-title":"Circulation"},{"key":"2862_CR81","doi-asserted-by":"publisher","first-page":"9032378","DOI":"10.1155\/2021\/9032378","volume":"2021","author":"L D\u2019Marco","year":"2021","unstructured":"D\u2019Marco L, Morillo V, Gorriz JL, Suarez MK, Nava M, Ortega \u00c1, et al. SGLT2i and GLP-1RA in cardiometabolic and renal diseases: from glycemic control to adipose tissue inflammation and senescence. J Diabetes Res. 2021;2021:9032378. https:\/\/doi.org\/10.1155\/2021\/9032378.","journal-title":"J Diabetes Res"},{"issue":"15","key":"2862_CR82","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"24","key":"2862_CR83","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744.","journal-title":"N Engl J Med"},{"issue":"1","key":"2862_CR84","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11883-022-00982-3","volume":"24","author":"P Novodvorsk\u00fd","year":"2022","unstructured":"Novodvorsk\u00fd P, Haluz\u00edk M. The effect of GLP-1 receptor agonists on postprandial lipaemia. Curr Atheroscler Rep. 2022;24(1):13\u201321. https:\/\/doi.org\/10.1007\/s11883-022-00982-3.","journal-title":"Curr Atheroscler Rep"},{"issue":"2","key":"2862_CR85","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"issue":"23","key":"2862_CR86","doi-asserted-by":"publisher","first-page":"12941","DOI":"10.3390\/ijms252312941","volume":"25","author":"M Adamczak","year":"2024","unstructured":"Adamczak M, Kurnatowska I, Naumnik B, Stomp\u00f3r T, Tylicki L, Krajewska M. Pharmacological nephroprotection in chronic kidney disease patients with type 2 diabetes mellitus\u2014Clinical practice position statement of the Polish society of nephrology. Int J Mol Sci. 2024;25(23):12941. https:\/\/doi.org\/10.3390\/ijms252312941.","journal-title":"Int J Mol Sci"},{"issue":"22","key":"2862_CR87","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/jama.2020.22258","volume":"324","author":"SJ Nicholls","year":"2020","unstructured":"Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324(22):2268\u201380. https:\/\/doi.org\/10.1001\/jama.2020.22258.","journal-title":"JAMA"},{"issue":"9784","key":"2862_CR88","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of Lowering LDL cholesterol with Simvastatin plus Ezetimibe in patients with chronic kidney disease (Study of heart and renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181\u201392. https:\/\/doi.org\/10.1016\/S0140-6736(11)60739-3.","journal-title":"Lancet"},{"issue":"1","key":"2862_CR89","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"issue":"5","key":"2862_CR90","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1056\/NEJMc2306575","volume":"390","author":"VJ Alexander","year":"2024","unstructured":"Alexander VJ, Karwatowska-Prokopczuk E, Prohaska TA, Li L, Geary RS, Gouni-Berthold I, et al. Volanesorsen to prevent acute pancreatitis in hypertriglyceridemia. N Engl J Med. 2024;390(5):476\u20137. https:\/\/doi.org\/10.1056\/NEJMc2306575.","journal-title":"N Engl J Med"},{"issue":"6","key":"2862_CR91","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jacl.2022.08.008","volume":"16","author":"EA Oral","year":"2022","unstructured":"Oral EA, Garg A, Tami J, Huang EA, O\u2019Dea LSL, Schmidt H, et al. Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: results of the BROADEN study. J Clin Lipidol. 2022;16(6):833\u201349. https:\/\/doi.org\/10.1016\/j.jacl.2022.08.008.","journal-title":"J Clin Lipidol"},{"issue":"5","key":"2862_CR92","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","volume":"9","author":"I Gouni-Berthold","year":"2021","unstructured":"Gouni-Berthold I, Alexander VJ, Yang Q, Hurh E, Steinhagen-Thiessen E, Moriarty PM, et al. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9(5):264\u201375. https:\/\/doi.org\/10.1016\/S2213-8587(21)00046-2.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2862_CR93","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381(6):531\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1715944.","journal-title":"N Engl J Med"},{"issue":"2","key":"2862_CR94","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa2409368","volume":"392","author":"GF Watts","year":"2025","unstructured":"Watts GF, Rosenson RS, Hegele RA, Goldberg IJ, Gallo A, Mertens A, et al. Plozasiran for managing persistent chylomicronemia and pancreatitis risk. N Engl J Med. 2025;392(2):127\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2409368.","journal-title":"N Engl J Med"},{"issue":"10","key":"2862_CR95","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2404143","volume":"391","author":"CM Ballantyne","year":"2024","unstructured":"Ballantyne CM, Vasas S, Azizad M, Clifton P, Rosenson RS, Chang T, et al. Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia. N Engl J Med. 2024;391(10):899\u2013912. https:\/\/doi.org\/10.1056\/NEJMoa2404143.","journal-title":"N Engl J Med"},{"issue":"7","key":"2862_CR96","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","volume":"9","author":"D Gaudet","year":"2024","unstructured":"Gaudet D, Pall D, Watts GF, Nicholls SJ, Rosenson RS, Modesto K, et al. Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial. JAMA Cardiol. 2024;9(7):620\u201330. https:\/\/doi.org\/10.1001\/jamacardio.2024.0959.","journal-title":"JAMA Cardiol"},{"issue":"6","key":"2862_CR97","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.5114\/aoms\/141941","volume":"17","author":"M Banach","year":"2021","unstructured":"Banach M, Burchardt P, Chlebus K, Dobrowolski P, Dudek D, Dyrbu\u015b K, et al. PoLA\/CFPiP\/PCS\/PSLD\/PSD\/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci. 2021;17(6):1447\u2013547. https:\/\/doi.org\/10.5114\/aoms\/141941.","journal-title":"Arch Med Sci"},{"key":"2862_CR98","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.atherosclerosis.2021.04.014","volume":"327","author":"LF Reeskamp","year":"2021","unstructured":"Reeskamp LF, Nurmohamed NS, Bom MJ, Planken RN, Driessen RS, van Diemen PA, et al. Marked plaque regression in homozygous Familial hypercholesterolemia. Atherosclerosis. 2021;327:13\u20137. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.04.014.","journal-title":"Atherosclerosis"},{"issue":"18","key":"2862_CR99","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","volume":"145","author":"BA Bergmark","year":"2022","unstructured":"Bergmark BA, Marston NA, Bramson CR, Curto M, Ramos V, Jevne A, et al. Effect of Vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70. Circulation. 2022;145(18):1377\u201386. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.059266.","journal-title":"Circulation"},{"issue":"9","key":"2862_CR100","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1001\/jamacardio.2023.2222","volume":"8","author":"SJ Lee","year":"2023","unstructured":"Lee SJ, Cha JJ, Choi WG, Lee WS, Jeong JO, Choi S, et al. Moderate-intensity Statin with Ezetimibe combination therapy vs high-intensity Statin monotherapy in patients at very high risk of atherosclerotic cardiovascular disease: A post hoc analysis from the RACING randomized clinical trial. JAMA Cardiol. 2023;8(9):853\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2023.2222.","journal-title":"JAMA Cardiol"},{"issue":"11","key":"2862_CR101","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007784.pub3","volume":"11","author":"DJ Tunnicliffe","year":"2023","unstructured":"Tunnicliffe DJ, Palmer SC, Cashmore BA, Saglimbene VM, Krishnasamy R, Lambert K, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2023;11(11):CD007784. https:\/\/doi.org\/10.1002\/14651858.CD007784.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2862_CR102","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-024-02276-w","volume":"23","author":"I Bellos","year":"2024","unstructured":"Bellos I, Lagiou P, Benetou V, Marinaki S. Efficacy and safety of statin therapy in kidney transplant recipients: a systematic review and meta-analysis. Lipids Health Dis. 2024;23(1):293. https:\/\/doi.org\/10.1186\/s12944-024-02276-w.","journal-title":"Lipids Health Dis"},{"issue":"6","key":"2862_CR103","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/ki.2014.31","volume":"85","author":"C Wanner","year":"2014","unstructured":"Wanner C, Tonelli M. Kdigo clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85(6):1303\u20139. https:\/\/doi.org\/10.1038\/ki.2014.31.","journal-title":"Kidney Int"},{"issue":"23","key":"2862_CR104","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","volume":"73","author":"DM Charytan","year":"2019","unstructured":"Charytan DM, Sabatine MS, Pedersen TR, Im KA, Park JG, Pineda AL, et al. Efficacy and safety of Evolocumab in chronic kidney disease in the FOURIER trial. J Am Coll Cardiol. 2019;73(23):2961\u201370. https:\/\/doi.org\/10.1016\/j.jacc.2019.03.513.","journal-title":"J Am Coll Cardiol"},{"issue":"42","key":"2862_CR105","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1093\/eurheartj\/ehaa498","volume":"41","author":"J Tu\u00f1\u00f3n","year":"2020","unstructured":"Tu\u00f1\u00f3n J, Steg PG, Bhatt DL, Bittner VA, D\u00edaz R, Goodman SG, et al. Effect of Alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. Eur Heart J. 2020;41(42):4114\u201323. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa498.","journal-title":"Eur Heart J"},{"key":"2862_CR106","doi-asserted-by":"publisher","first-page":"13457","DOI":"10.1038\/ncomms13457","volume":"7","author":"SL Pinkosky","year":"2016","unstructured":"Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, et al. Liver-specific ATP-citrate lyase Inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016;7:13457. https:\/\/doi.org\/10.1038\/ncomms13457.","journal-title":"Nat Commun"},{"key":"2862_CR107","doi-asserted-by":"publisher","first-page":"1551136","DOI":"10.3389\/fimmu.2025.1551136","volume":"16","author":"L Peng","year":"2025","unstructured":"Peng L, Lai W, Yu S, Li Q, Jiang X, Chen G. GLP-1 and glucagon receptor dual agonism ameliorates kidney allograft fibrosis by improving lipid metabolism. Front Immunol. 2025;16:1551136. https:\/\/doi.org\/10.3389\/fimmu.2025.1551136.","journal-title":"Front Immunol"},{"issue":"1","key":"2862_CR108","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41581-021-00488-2","volume":"18","author":"J Baek","year":"2022","unstructured":"Baek J, He C, Afshinnia F, Michailidis G, Pennathur S. Lipidomic approaches to dissect dysregulated lipid metabolism in kidney disease. Nat Rev Nephrol. 2022;18(1):38\u201355. https:\/\/doi.org\/10.1038\/s41581-021-00488-2.","journal-title":"Nat Rev Nephrol"},{"issue":"14","key":"2862_CR109","doi-asserted-by":"publisher","first-page":"e70083","DOI":"10.1002\/mnfr.70083","volume":"69","author":"D Nascimento","year":"2025","unstructured":"Nascimento D, Britto I, Couto H, Alvarenga L, Cardozo LFMF, Berretta AA, et al. Effects of a functional food mixture on patients undergoing hemodialysis: preliminary results highlighting the modulation of uremic toxins derived from microbiota and antioxidant markers. Mol Nutr Food Res. 2025;69(14):e70083. https:\/\/doi.org\/10.1002\/mnfr.70083.","journal-title":"Mol Nutr Food Res"},{"issue":"4","key":"2862_CR110","doi-asserted-by":"publisher","first-page":"e172963","DOI":"10.1172\/JCI172963","volume":"134","author":"D Mukhi","year":"2024","unstructured":"Mukhi D, Li L, Liu H, Doke T, Kolligundla LP, Ha E, et al. ACSS2 gene variants determine kidney disease risk by controlling de Novo lipogenesis in kidney tubules. J Clin Invest. 2024;134(4):e172963. https:\/\/doi.org\/10.1172\/JCI172963.","journal-title":"J Clin Invest"},{"issue":"4","key":"2862_CR111","doi-asserted-by":"publisher","first-page":"e178125","DOI":"10.1172\/JCI178125","volume":"134","author":"H Li","year":"2024","unstructured":"Li H, Humphreys BD. Targeting de Novo lipogenesis to mitigate kidney disease. J Clin Invest. 2024;134(4):e178125. https:\/\/doi.org\/10.1172\/JCI178125.","journal-title":"J Clin Invest"},{"issue":"5","key":"2862_CR112","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/toxins17050217","volume":"17","author":"C Freise","year":"2025","unstructured":"Freise C, Metzkow S, Zappe A, Ebert M, Stolzenburg N, Hahndorf J, et al. The uremic toxins inorganic phosphate, indoxylsulphate, p-Cresylsulphate, and TMAO induce the generation of sulphated glycosaminoglycans in aortic tissue and vascular cells via pAKT signaling: A missing link in the Gut\u2013Matrix axis. Toxins (Basel). 2025;17(5):217. https:\/\/doi.org\/10.3390\/toxins17050217.","journal-title":"Toxins (Basel)"},{"key":"2862_CR113","doi-asserted-by":"publisher","unstructured":"Tang Y, Li Y, Yang X, Lu T, Wang X, Li Z, et al. Intestinal metabolite TMAO promotes CKD progression by stimulating macrophage M2 polarization through histone H4 lysine 12 lactylation. Cell Death Differ Published Online August. 2025;19. https:\/\/doi.org\/10.1038\/s41418-025-01554-z.","DOI":"10.1038\/s41418-025-01554-z"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-026-02862-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-026-02862-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-026-02862-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:49:27Z","timestamp":1781628567000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12944-026-02862-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":113,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2862"],"URL":"https:\/\/doi.org\/10.1186\/s12944-026-02862-0","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}